1 Big Pharma Giant on the Verge of a Turnaround

Pharma giant Sanofi hasn't had a bad year by any means: Its stock has recorded double-digit percentage gains, and the company's star diabetes treatment, Lantus, has continued to see strong growth despite already selling billions of dollars in revenues annually. However, Sanofi's stock has trailed some of the biggest names in big pharma this year, and the patent cliff has taken a toll on the company's sales outside of Lantus.

The company reported third-quarter results earlier this week that brought much of the same to investors, with both profit and revenue falling for the period. However, Sanofi's leadership has expressed optimism that this company's sales slump soon could be a thing of the past.

Is Sanofi primed for a turnaround? Find out in the video below, as Fool contributor Dan Carroll takes you through what Sanofi's recent performance means for this company's future and what investors should expect from this big pharma giant in the months and quarters ahead.

The simplest way to realizing your financial potential
Sanofi's looking ahead to the long-term with a new formulation of Lantus ready to take over for the original's coming patent expiration. Are you investing with that same long-term horizon? You should be: After all, the best investing approach is to choose great companies and stick with them for years. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article 1 Big Pharma Giant on the Verge of a Turnaround originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.